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Purpose: To characterize the clinical features of a Chinese pedigree with Blau syndrome and to identify mutations in the
NOD2/CARD15 (nucleotide-binding oligomerization domain containing 2/caspase recruitment domain family, member
15) gene.
Methods: Clinical features of this family were evaluated. Genomic DNA was obtained from blood samples, and all exons
of NOD2/CARD15 were amplified by polymerase chain reaction (PCR) and direct DNA sequencing of PCR products was
performed for mutations in NOD2/CARD15.
Results: Granulomatous arthritis, uveitis, and skin granulomas were found in all affected members. Sequencing analysis
demonstrated a heterozygous C>T mutation in exon 4 of NOD2/CARD15 in all patients of this pedigree, which resulted
in an amino acid substitution at position 334 (p.R334W).
Conclusions: The R334W mutation in NOD2/CARD15 caused Blau syndrome in a Chinese pedigree. This is the first
report of R334W mutation in NOD2/CARD15 in a Chinese pedigree of this disease.
Blau syndrome (BS, OMIM 186580) is a rare, autosomal
dominant and autoinflammatory disorder with an onset under
4 years of age, which is characterized by clinical triad of
symmetric  arthritis,  recurrent  uveitis,  and  granulomatous
dermatitis [1]. The disease was first described by Blau in 1985
[2], and then a similar family was reported by Jabs et al. [3]
in the same year. Mutations in NOD2/CARD15 (nucleotide-
binding  oligomerization  domain  containing  2/caspase
recruitment domain family, member 15) were first identified
to be associated with susceptibility to Crohn's disease (CD)
[4],  which  improved  our  knowledge  of  systemic
autoinflammatory  disorders.  Subsequently,  the  same  gene
defects  in  families  with  Blau  syndrome  and  early  onset
sarcoidosis (EOS) have also been described [5,6].
The NOD2 (nucleotide-binding oligomerization domain
containing 2) gene, also termed CARD15 (caspase recruitment
domain family, member 15), is located on chromosome 16q12
and encodes multidomain protein of 1,040 amino acids. The
NOD2 protein is primarily expressed in antigen-presenting
cells, such as monocytes and macrophages, and in intestinal
Paneth cells [7]. It plays an important role in the immune
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response to intracellular bacterial lipopolysaccharides (LPS)
by activating the nuclear regulatory factor (NF)-kB (nuclear
factor-kappa B) pathway of inflammation and apoptosis [8].
Subsequent  researches  of  the  pathogenic  mechanism
responsible  for  the  chronic  inflammation  are  still  under
investigation. The most common NOD2/CARD15 mutations
in Blau Syndrome were found in codon 334 (R334W and
R334Q) in French, German [6], Japanese [9,10], and Italian
[11] families, while other mutations have also been reported,
such as T605N [12], E383K [11,13], and L469F [11].
In this study, we conducted a clinical evaluation and
mutational analysis of NOD2/CARD15 in a Chinese family
with  Blau  syndrome.  The  R334W  mutation  of  NOD2/
CARD15  was  identified  in  all  affected  member  of  this
pedigree. To the best of our knowledge, this is the first report
of R334W mutation in NOD2/CARD15 in a pedigree with this
disease in Asia except Japan [9,10].
METHODS
Patients: The study was approved by West China Hospital,
Sichuan University Institute Review Board, and performed
according to the principles of the Declaration of Helsinki.
Informed consent was obtained from all participants. Three
patients and four unaffected individuals, with age from 16 to
68 years old, were enrolled in this study. No consanguineous
marriage was noticed in the family (Figure 1).
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617Clinical  examination:  All  individuals  underwent
ophthalmological  examinations,  including  Snellen  best-
corrected visual acuity, detailed slit-lamp examination, and B-
scan Ophthalmic Ultrasound. Blood tests for autoantibody to
nuclear  antigen  (ANA),  anti-streptolysin  O  (ASO),
rheumatoid  factor  (RF),  human  leucocyte  antigen-27
(HLA-27),  C-reactive  protein  (CRP),  and  erydlrocyte
erythrocyte sedimentation rate (ESR) were performed. X-rays
of joints and chest and computed tomography (CT) scans were
performed in all patients.
Molecular genetic analysis: Peripheral blood was collected
for DNA analysis from three patients and four unaffected
individuals involved in this study. Genomic DNA was isolated
from  leukocytes  using  QIAamp  DNA  Blood  Mini  Kit
(Qiagen, Hilden, Germany) by standard protocols. Coding
sequences  of  NOD2/CARD15  (exons  1–12,  GenBank
NG_007508.1) were amplified from genomic DNA using the
forward and reverse primers shown in Table 1. Each 30 µl
PCR amplification reaction was performed with 30–40 ng
genomic DNA, 1.0 μM of each of the forward and reverse
primers and 15 μl of 2× Taq Master Mix (SinoBio Biltech Co.
Ltd, Shanghai, China). The modified thermal profile consisted
of an initial denaturation step at 94 °C for 5 min, followed by
a 35 cycles of denaturation at 94 °C for 30s, then annealing at
55 °C for 30 s and extension at 72 °C for 30 s, and a final
extension at 72 °C for 5 min. The amplified products were
purified with a cycle-pure kit (OMEGA; BioTek, Doraville,
GA) and sequenced on the ABI 3730XL automated DNA
sequencer (Applied Biosystems, Foster City, CA). Sequence
data were compared pair-wise with wild type NOD2 sequence
(GenBank NG_007508.1).
The mutation was named according to the nomenclature
recommended  by  the  Human  Genomic  Variation  Society
(HGVS).
RESULTS
Clinical findings: The proband (III:5, Figure 1), a 20-year-old
female, presented with a cutaneous eruption of discrete small
papules when she was 3 years old, which was noticed by her
mother.  After  several  months,  the  skin  rash  faded  away
spontaneously without therapy, but subsequently recurred and
persisted for months. At the age of 4, she had arthritis with
periarticular  swelling  of  metacarpophalangeal  (MCP)  and
proximal  interphalangeal  (PIP)  joints  with  no  function
problems. A few years later, she was diagnosed with juvenile
rheumatoid  arthritis  (JRA),  and  treated  with  non-steroidal
anti-inﬂammatory drugs (NSAIDs) initially and later, with
intermittent courses of prednisone. Figure 2D revealed the
deformities of the proband’s hands. At the age of 13, she had
bilateral  anterior  uveitis  and  was  treated  with  different
dosages  of  topical  corticosteroids,  NSAIDs  and
immunosuppressive agents Cyclosporin A, which seemed to
be ineffective in the treatment of uveitis. Secondary closed-
angle glaucoma was found on her left eye when she was 15
years  old.  Trabeculectomy  was  then  performed  and
intraocular pressure (IOP) was well controlled. Two years
later  after  the  operation,  IOP  began  to  rise  up  to  about
40 mmHg on her right eye. Carteolol and brinzolamide were
tried  but  failed  to  control  IOP.  She  underwent  peripheral
iridectomy on the right eye. Now IOPs were well controlled
in  both  eyes  without  any  antiglaucoma  medications.  The
uveitis progressed to the persistent fulminant panuveitis. The
present visual acuity was CF (count fingers) OD and 20/400
OS.  Anterior  segment  examination  demonstrated  bilateral
band-shaped degeneration of cornea near the limbus and dot-
like calcific keratopathy in Bowman's membrane (Figure 2G).
The  slit-lamp  examination  showed  extensive  posterior
synechia of the iris (which caused occlusion of pupil) and
opacity  in  the  lens  on  her  both  eyes.  Bilateral  extensive
goniosynechia  and  closed  angles  were  showed  under
Figure 1. Pedigree of a Chinese family with Blau syndrome. The filled squares and circles indicate affected individuals. Arrow indicates the
proband. The asterisks indicate the individuals who had undergone clinical and molecular genetic analyses in the study.
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618gonioscopy. B-scan Ophthalmic Ultrasound showed scattered
flocculent  or  dot  echo  in  the  vitreous.  Blood  tests  for
autoantibody to nuclear antigen (ANA), anti-streptolysin O
(ASO), rheumatoid factor (RF), human leucocyte antigen-27
(HLA-27) and C-reactive protein (CRP) were negative, and
erythrocyte  sedimentation  rate  (ESR)  was  within  normal
limits.  X-rays  and  CT  scans  revealed  periarticular
osteoporosis and erosion of bone at the edges of the joint. The
joint space became narrow and subluxation at some MCP and
PIP joints, while Chest X-ray was normal.
The proband’s brother (III:6, Figure 1), a 16-year-old
male, presented with periarticular swelling of the wrists, MCP
and proximal PIP joints followed by exanthema on the face,
trunk and extremities at the age of 4. During the course of the
disease, the patient got recurrent episodes of skin rashs on the
face and extremities. Figure 2A showed the deformities of the
MCP and PIP joints. He had mild anterior uveitis at the age
of 13. Thesymptoms and signs were well controlled with low
doses of prednisone and NSAIDs. His current best corrected
visual  acuity  was  20/25  OD  and  20/20  OS.  Slit-lamp
examination revealed partial posterior synechia from 2:30 to
3:00 and 9:30 to 10:30 of the iris on his right eye (Figure 2C).
His blood tests for ANA, ASO, RF, HLA-27, and CRP were
also negative, ESR was within normal limits. The coronal
reconstruction section of CT scans showed erosion of bone at
the  edges  of  the  joint  in  the  MCP  joints  andjoint  space
narrowing and subluxation in the PIP joints (Figure 2B). Chest
X-ray was normal. The diagnosis was juvenile rheumatoid
arthritis then.
The proband’s father (II:5, Figure 1), a 43-year-old male,
presented with MCP and PIP joint changes resembling their
children  at  the  age  of  about  6  but  not  manifested  with
exanthema. He also had slight anterior uveitis at the age of 25,
and his best corrected visual acuity was 20/20 OD and 20/20
OS. The ocular manifestation was partial posterior synechia
similar  to  his  son.  His  blood  tests  for  ANA,  ASO,  RF,
HLA-27, and CRP were negative, ESR was within normal
limits. Chest X-ray was also normal. X-rays of his both hands
showed  multiple  and  symmetric  joint  involvement,
generalized  osteoporosis,  joint  space  narrowing,  poorly
defined edges of the articular surfer, subluxation, contracture
and ankylosis of the PIP joints (Figure 2E,F).
NOD2/CARD15 analysis: All exons of NOD2/CARD15 of the
affected and unaffected individuals included in this study
were analyzed by direct sequencing. A heterozygous mutation
C>T transversion in exon 4 was identified in each patient,
which resulted in an amino acid substitution from Arginine
(CGG) to Tryptophan (TGG) at codon 334 (R334W). No such
mutation was found in unaffected members who were taken
as controls in the family (Figure 3).
TABLE 1. PRIMERS USED IN POLYMERASE CHAIN REACTION FOR AMPLIFICATION OF NOD2/CARD15.
Exon Annealing
temperature (°C)
Primer direction Sequence (5′→3′) Amplicon size (bp)
1 55.0 Forward GTAGACAGATCCAGGCTCAC 384
    Reverse ACCAGCCAAGGATGCGACAG  
2 55.0 Forward TGACCACCCTGCATCTGGCTT 627
    Reverse ACCAAGTTACCCCACAGGCTG  
3 55.0 Forward CAGTAAGCCTTCCCACATTG 451
    Reverse AACACCTTTAGTTAGCCCTCA  
4a 55.0 Forward CTGGCTCTCCTATCCCTTCA 555
    Reverse TGTCTTCTTGACCAACATCAG  
4b 55.0 Forward TCTCTTTGTCTTCCCATTCAG 462
    Reverse AGGGCTGAGGTCTCTTGGA  
4c 55.0 Forward GCTTCTCTGAACAGGGCATC 689
    Reverse TGCTGTGATCTGAAGGTTGTG  
4d 55.0 Forward AGGTGTCGTGCCAGGGAGTA 755
    Reverse CACACTTAGCCTTGATGGTG  
5,6 55.0 Forward GCACAGATGCTGGCACTTC 565
    Reverse CAGATCAGACTGACTCAGGAAT  
7 55.0 Forward GTAAACTAGACCTAGCAGCGA 277
    Reverse CTCCATGCAGGTCCCTCTTC  
8 55.0 Forward GGAGGAGGACTGTTAGTTCAT 362
    Reverse AGAGGACAAGGGACATTTCCA  
9 55.0 Forward AGACCAGGAGAGCACCACGA 301
    Reverse CAGTCAATCACTCAATCATCCA  
10 55.0 Forward TGTGAGTTCATCATCTTCCATA 297
    Reverse ATCCTTGTCCACCTAGACCA  
11 55.0 Forward CTCATTGGGAATCTCAGACAT 391
    Reverse CAGAGAATCAGATCCTTCACAT  
12 55.0 Forward GAGAGTCAGCCCATCCCAG 476
    Reverse AGCAGAGGCCAGTCCCATACT  
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Sarcoidosis is a systemic inflammatory disease characterized
by swelling of the bilateral hilar lymph nodes and the presence
of  noncaseating  epithelioid  cell  granulomas.  As  a  special
subtype of sarcoidosis, early-onset sarcoidosis (EOS) occurs
in children younger than 4 years of age and is characterized
by a distinct triad of skin, joint, and eye disorders [14]. Blau
syndrome  (BS),  which  demonstrates  similar  clinical
manifestations as EOS, has been described as a fixed triad of
multiorgan  granulomatous  arthritis,  uveitis  and  dermatitis
with a clear dominant inheritance pattern [1]. Since 1996 the
BS locus was mapped to chromosomal 16p12-q21 [15] and
NOD2/CARD15 was subsequently identified in that region to
be  associated  with  the  disease  [6],  more  than  14  NOD2/
CARD15 mutations have been described in many different
countries, and have been shown to affect the residue Arg334,
which may be a genetic “hot spot” for mutations in patients
with  some  familial  granulomatoses  [6,12,16,17].  Previous
Figure 2. Representative photographs of arthritis and uveitis of patients in the family. A: General appearance showed deformities of the feet
in patient (III:6). B: The coronal reconstruction section of CT scan of patient (III:6) revealed erosion of bone at the edges of the joint in the
MCP joints, joint space narrowing and subluxation in the proximal interphalangeal (PIP) joints (yellow arrow). C: The right eye of the patient
(III:6) revealed partial posterior synechia (blue arrow). D: Deformity of the hands of the proband (III:5). E and F: X-rays of patient (II:5)
showed multiple and symmetric joint involvement, generalized osteoporosis, joint space narrowing, poorly defined edges of the articular
surfer, subluxation, contracture and ankylosis of the PIP joints (white arrow). G: the right eye of the proband (III:5) showed dot-like calcific
keratopathy in Bowman's membrane and the cornea between the opacities remained clear (red arrow).
Figure 3. NOD2/CARD15 heterozygous
mutation  in  the  family.  A:  A
heterozygous mutation consisting of a
C>T transversion in exon 4 (red arrow)
was identified. B: Wild type sequence
from  an  unaffected  member  (black
arrow).
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620studies showed BS shared considerable pathologic, clinical
and therapeutic overlap with sarcoidosis, but no subject of BS
has yet manifested sarcoidlike lung disease [18,19]. Other
granulomatous diseases such as Wegener’s granulomatosis
and  ordinary  sarcoidosis  have  not  been  associated  with
NOD2/CARD15 [20-23], while the affected individuals with
EOS which also have a NOD2/CARD15 mutation were always
sporadic cases without family history of the disease [14].
Besides the symptoms of arthritis, uveitis and dermatitis,
some atypical clinical features such as central nervous system
involvement,  interstitial  pneumonitis,  liver  involvement,
sinus of valsalva aneurysm, periodic fever, and leg ulcers were
also reported during the course of the disease [24-29]. In this
study,  the  pedigree  is  inherited  as  an  obvious  autosomal
dominant trait with early onset below the age of 4. The two
patients manifested typical granulomatous arthritis, anterior
uveitis  and  skin  rash  of  BS,  while  the  proband’s  father
presented with both arthritis and uveitis but no manifestation
of dermatitis. The changes in joints were noticed in the early
age of onset of all patients. None of the patients had lung and
other organs involvement. The female proband, compared
with  her  father  and  brother,  presented  with  more  severe
anterior uveitis companied by glaucoma and cataract. Besides,
the age of disease onset was later in the father than in the son
and  daughter.  This  suggests  a  possible  case  of  genetic
anticipation, which has been reported in several BS families
[12,17,30,31]. From a clinical point of view, the presence of
multiple  atypical  manifestations,  the  occurrence  of
incomplete forms of the classic triad, and the varying degrees
of severity from case to case confirmed the presence of a
degree of clinical heterogeneity in BS, even in patients from
the same family [17,32]. Interestingly, some studies suggested
that BCG (Bacillus Calmette-Guerin) vaccination and other
microorganisms may be an obvious triggering factor in the
ocular and joint inflammation seen in BS [33-35]. The case
herein reported further demonstrates the heterogeneity of BS
that should be taken into account when genetic screening is
performed in those cases with atypical presentation.
Almost all the patients in this family were originally
misdiagnosed as juvenile rheumatoid arthritis (JRA). JRA had
also been reported in other patients with BS [2,12,36], the
main reason for the incorrect diagnosis could be the high
prevalence of JAR and the similar clinical features of the
joints.  In  this  pedigree,  mutational  analysis  of  NOD2/
CARD15  revealed  a  heterozygous  mutation  (R334W)
previously  detected  in  other  Blau  syndrome  pedigrees  in
different  ethnic  nationalities  and  countries  [6,37,38].  It  is
considerately significant to distinguish this genetic disease
from other pediatric arthritis, such as juvenile rheumatoid
arthritis, juvenile ankylosingspondylitis and EOS not only for
treatment  but  also  for  genetic  counseling  and  prenatal
diagnosis.  Until  now,  no  asymptomatic  carriage  has  been
reported,  so  molecular  genetic  analysis  rather  than  tissue
sampling may prove to be the most efficient way to make an
accurate diagnosis [39].
Despite the causative genes have been identified, the
molecule mechanism and the pathogenesis of the disorder is
not fully understood. NOD2/CARD15 is a member of the
Nod1/Apaf-1 family, It encodes a cytosolic protein termed
nucleotide oligomerization domain 2 (Nod2), comprising two
caspase  recruitment  domains  (CARD):  a  nucleotide
oligomerisation domain (NOD), and a stretch of leucine rich
repeats (LRRs) [40]. The Nod2 protein, a cytosolic receptor
which belongs to the group of Nod-like receptors (NLRs)
plays  an  important  role  in  the  immune  response  against
bacterial peptidoglycan by inducing signaling pathways such
as NF-kB (nuclear factor kappaB) and MAPKs (mitogen-
activated protein kinases) [41]. Constitutive NF-kB activation
was found in majority of EOS and BS cases which may share
the  common  genetic  etiology  of  NOD2/CARD15  [42].
Mutations of the NOD and LRR seem to result in different
phenotypic  consequences  within  the  spectrum  of
granulomatous disorders. For example, the Crohn's disease-
associated CARD15 mutations are located in or close to the
LRRs region, while Blau syndrome mutations were found to
cluster in the NOD [20,43]. McDonald et al. suggested Erbin,
a protein involved in cell polarity, receptor localization, and
regulation of the mitogen-activated protein kinase pathway,
as a regulator of Nod2 signaling [44].
Collectively, our results demonstrate that the R334W
mutation of NOD2/CARD15 caused BS in a Chinese pedigree.
Molecular  genetic  analysis  is  necessary  to  establish  the
appropriate diagnosis of BS. This is the first report of an
R334W mutation in NOD2/CARD15 in a Chinese population
with  BS.  Obviously,  more  studies  of  the  molecule
pathomechanisms of BS are needed in further investigations.
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